AwardedUnited KingdomServices£272,700
Oncotype DX Breast Cancer Testing
- Published
- Published 3 March 2026
- Deadline
- Closed 4 February 2026
Overview
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy
decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into
groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient.
Additional information:
This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
Key details
- Country
- United Kingdom
- Status
- Awarded
- Category
- Services
- Estimated value
- £272,700
- Procedure
- Selective
- SME suitable
- No
- Published
- 3 March 2026
- Deadline
- Closed
Pathology services
Award outcome
- Awarded value
- £272,700
- Award date
- 2 March 2026
- Contract period
- 31 March 2026 → 31 March 2027
- Exact Sciences UK, Ltd.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
3 March 2026
Contracting authority
East Sussex Healthcare NHS Trust
BuyerSaint Leonards-on-sea, United Kingdom
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.